Latest Financial Position News

Verity Resources has confirmed a new mineralised gold zone at its Monument Gold Project in Western Australia and successfully raised approximately $600,000 through a recent rights issue, positioning the company for further exploration and development.

Helios Energy has made significant strides in advancing its flagship Presidio Project in Texas, confirming substantial hydrocarbon resources and strengthening its leadership and financial position.

Venus Metals Corporation reports compelling gold assay results from its Henderson and Sandstone projects, alongside advancing mining lease applications and maintaining a robust cash position of $12.4 million.

ABx Group reports significant progress in its rare earths and bauxite ventures, including enhanced geological models and pilot plant developments supported by key partnerships and government backing.

Axel REE Limited reports a breakthrough in its Brazilian exploration with record high-grade rare earth and gallium assays at the Caladão Project, expanding the mineralised area significantly and securing funding to advance resource definition.

Lefroy Exploration has reported significant mineral resource upgrades at Burns Central and Mt Martin, alongside a strategic exclusivity agreement with BML Ventures to develop the Lucky Strike Gold Project.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Lefroy Exploration Limited reported a modest net cash decrease in the December quarter, ending with $3.24 million in cash reserves and nearly four quarters of funding available. The company continues to invest heavily in exploration activities despite operating cash outflows.

Gratifii reports a remarkable 110% increase in 2Q FY25 cash receipts, driven by strategic acquisitions and strong client engagement, setting the stage for sustained growth and profitability in the coming quarters.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Stonehorse Energy Limited outperformed production forecasts in Q4 2024 despite a revenue dip caused by weak natural gas prices, while advancing new project negotiations in Canada and the US.

Imugene Limited reports durable patient responses in multiple cancer immunotherapy trials and strengthens its financial position with a $46 million convertible note deal and a substantial R&D tax refund.